Placenta encapsulation

1. Introduction

Version followed: placenta encapsulation as US and UK provider and training organisations describe it (the ProDoula Postpartum Placenta Specialist route, the Association of Placenta Preparation Arts (APPA), a provider-marketplace description, and the UK Independent Placenta Encapsulation Network as reported in 2014), set against CDC, NICE, NHS Wales and peer-reviewed sources. This guide sets out the psychotherapist's own work alongside a commercial service; the psychotherapist never performs, sells, prescribes or recommends it.

What it is. After birth, the birthing parent's placenta is collected by a paid "placenta specialist", processed off-site and returned, most often as capsules to be swallowed in the postpartum weeks. Providers also offer raw preparations (e.g. smoothies), tinctures, and non-ingested keepsakes such as placenta prints and dried umbilical-cord mementos. [source: ProDoula training page; Bornbir provider guide; British Journal of Midwifery 2014]

Its theory of change, as providers state it. The placenta, which nourished the baby, is "repurposed" to support recovery; providers compare capsules to a daily vitamin and attribute effects to placental hormones (e.g. oxytocin, CRH) and iron that are said to help rebalance the hormonal drop after birth. Two named preparation philosophies are offered, a "raw" approach and a "Traditional" or TCM-inspired approach; one provider guide states there is no scientific evidence that either is superior. Benefits claimed by providers and parents include better mood and fewer "baby blues", more energy, better milk supply and lighter postpartum bleeding; proponents also argue that placenta-eating is common among other mammals. These are the method's own claims, attributed here, not established effects. [source: Bornbir provider guide; UNLV 2017 news release; British Journal of Midwifery 2014]

Evidence status (one line). A 2015 Northwestern review of 10 studies found no human or animal data supporting claims for mood, pain, energy, lactation, bonding or iron; a 2017 UNLV pilot placebo-controlled trial (12 capsule vs 15 placebo) found little or no effect on mood, bonding or fatigue, with small hormone changes of unknown significance; a 2023 matched cohort (n=3,752 matched) found consumers had slightly higher, not lower, postpartum depression screening scores, which the authors think likely reflects higher-risk women choosing it. [source: Northwestern 2015; UNLV 2017; Benyshek, Bovbjerg & Cheyney 2023]

Regulatory status (one line per jurisdiction).

US: CDC states that no standards exist for processing placenta for consumption; a legal scholar argues the FDA "needs to begin regulating" it, implying no specific federal regime at present; birth-setting release policies vary. State placenta-release laws [uncertain: not verified]. [source: CDC MMWR 2017; Donley, The Regulatory Review]
UK: in 2014 the Food Standards Agency (FSA) said it considered placenta a "novel food" (no evidence of significant consumption before 1997), which would bar marketing until authorised; local councils issued Hygiene Emergency Prohibition Notices to one provider and a district judge confirmed an order that raw placenta must not be processed for human consumption. A current NHS Wales health-board leaflet instead tells women to choose a provider registered as a food business with local environmental health and holding a food hygiene rating. How these two positions are reconciled today [uncertain: sources conflict; current FSA position not verified]. [source: British Journal of Midwifery 2014; NHS Wales Hywel Dda guideline 1005]
Other jurisdictions (Canada, Australia, Ireland, EU states) [uncertain: not verified].

Who practises it. Mainly doulas and self-described placenta specialists who hold private certificates. Certification is a private business: e.g. ProDoula's route is a two-day intensive (in person or virtual), a bloodborne-pathogens certificate, a food-handler course, a manual and cultural-competence reading, one documented encapsulation with photos and an online exam, for a fee plus annual membership; APPA describes itself as an international training and certification programme that also sells bloodborne-pathogens training. These certificates are not state licences. [source: ProDoula training page; APPA profile on Experiment.com]

2. Framework

Placenta encapsulation has no therapeutic phases of its own. Two sequences matter: what the client goes through with the provider, and the psychotherapist's parallel work.

A. The client's experience with a provider (as providers describe it, qualitatively only). [source: Bornbir provider guide; ProDoula training page; NHS Wales guideline 1005; CDC MMWR 2017]

Antenatal booking. The client books a provider and, in the provider literature, is told to inform the hospital, birth centre or midwife and check release policies. Some providers screen for some prior infections; in the CDC case the company did not ask about infections during or after labour.
At birth. The birth setting may ask the client to sign a human-tissue release form (NHS Wales). The placenta is handled by staff, put in a chilled container supplied by the provider, and collected.
Processing off-site. Providers describe processing the placenta into capsules (raw or a steamed/"Traditional" variant) or other products. No national processing standard exists (CDC). No preparation details are given here.
Return and use. Capsules are delivered with the provider's own instructions; the client takes them in the early postpartum period. Remains may need lawful disposal as human tissue (NHS Wales advises burial guidance).
Cost. One provider marketplace cites a typical package range of a few hundred US dollars.

B. The psychotherapist's parallel work [synthesis, built on NICE CG192 and CDC recommendations]

Phase 1, antenatal (from booking to birth): ask, record, explore meaning and expectations, support an informed decision, and make sure a perinatal mental health plan exists that does not depend on capsules. Move on when the client's decision and mental-health plan are recorded and, with consent, the midwife or obstetric team knows of the plan.
Phase 2, early postnatal (first weeks): check mood with the NICE-recommended questions and instruments, watch for severe illness and postpartum psychosis, keep the medical team informed of placenta use if the baby or parent becomes unwell. Move on when mood is monitored and any treatment need is acted on.
Phase 3, later postnatal: review outcomes, attributions ("the capsules worked" / "I failed"), regret or grief, and any harm; reporting where relevant.
Format and session count: not a stand-alone course; woven into perinatal therapy, revisited at each perinatal check-in. NICE timescales apply to mental health care itself: assessment within 2 weeks of referral and psychological intervention starting within 1 month of assessment. [source: NICE CG192 1.7.3]

3. Guiding principles

Curiosity, not judgement. NICE notes women may hide problems for fear of being judged as mothers or of losing the baby to care. Practical meaning: ask about placenta plans in the same tone as feeding or sleep plans. [source: NICE CG192 1.5.1]
Attribute, do not adjudicate. Practical meaning: say "providers say…" and "the research found…"; neither endorse nor ridicule the client's cultural, spiritual or personal reasons. [synthesis]
The psychotherapist never performs, sells, prescribes or recommends it. Practical meaning: no referrals to named encapsulators, no affiliate arrangements, no advice on preparation or how much to take. [synthesis; ethics code uncertain: not verified]
Capsules are never the mental health plan. No evidence shows they prevent postpartum depression. Practical meaning: every client who hopes capsules will protect mood also gets screening, monitoring and an evidence-based plan. [source: Northwestern 2015; Benyshek et al. 2023; NICE CG192]
Infant safety comes first. CDC advises that ingestion should be avoided and that clinicians ask about it in late-onset infant GBS infection. Practical meaning: make sure the paediatric and maternity teams can be told, and route any unwell-baby concern to urgent medical care. [source: CDC MMWR 2017]
Coordinate, with consent. Practical meaning: the midwife, obstetrician, GP, paediatrician or pharmacist hold the medical decisions; the psychotherapist shares information with consent and does not give medical advice. [synthesis]
Respect autonomy and values. NICE asks clinicians to discuss benefits, harms, uncertainty and the consequences of no treatment, using absolute numbers and decision aids. Practical meaning: give balanced information and leave the decision with the client. [source: NICE CG192 1.4.3, 1.4.6, 1.4.7]
Honour meaning separately from ingestion. The placenta can carry personal, spiritual or cultural meaning (NHS Wales names these reasons). Practical meaning: explore what the client wants to honour, and whether that need can be met in ways that carry no infection risk, without prescribing any ritual. [source: NHS Wales guideline 1005; synthesis]
Watch commerce and conflicts of interest. Practical meaning: notice when a client's doula, friend or community also sells the service; never have a financial interest yourself. [synthesis]

4. Intervention inventory

All interventions below are the psychotherapist's own work alongside the service. None involves handling, preparing, advising on or recommending placenta products. Risk flags appear where relevant.

4.1 Routine, non-judgemental inquiry and recording

Purpose / when: at antenatal intake and at the first postnatal session with any pregnant or recently delivered client; also whenever a client mentions "postpartum supplements", a doula package or "fourth trimester" plans. [synthesis]
Steps:
1. Ask as part of a general question about postpartum plans (feeding, sleep, help at home, supplements, "anything you plan to do with the placenta").
2. If yes, ask what form (capsules, raw, tincture, keepsake only), who provides it, and whether the midwife or birth setting knows.
3. Record factually in the notes: plan, provider type (not a recommendation), whether the maternity team is aware, and the client's stated reasons.
4. Note known risk markers to pass on with consent: CDC names GBS colonisation, chorioamnionitis (infection of the membranes) and an earlier early-onset GBS illness in the baby as reasons for particular caution. [source: CDC MMWR 2017]
Example language (illustrative): "Lots of people make plans for after the birth: feeding, sleep, supplements, sometimes something with the placenta. Is any of that on your list?" / "Thanks for telling me. I'll note it so we can keep your midwife in the loop if that's OK with you."
Watch for: shame or defensiveness (suggests the client expects judgement); a plan the maternity team does not know about; a plan presented mainly as protection against depression (go to 4.4). Working when: the client volunteers updates later without prompting.

4.2 Exploring meaning, hopes, expectations and explanatory model

Purpose / when: after disclosure, to understand what the plan does for the client. Providers frame it as a "vitamin", hormone rebalancing, a cultural tradition, "honouring the placenta" and part of "fourth trimester" self-care; proponents cite mammalian behaviour. Research suggests women learn of it largely through media, blogs and websites rather than clinicians. [source: Bornbir provider guide; ProDoula training page; Northwestern 2015]
Steps:
1. Ask what drew them to it and where they heard of it (friend, doula, social media, celebrity, family tradition).
2. Elicit the hoped-for effects in their own words (mood, energy, milk, bleeding, bonding) and how they would know it was working.
3. Explore the deeper need: control after an unpredictable birth, fear of a past depression returning, distrust of medicines while breastfeeding, a natural-birth identity, spiritual or cultural meaning, belonging in a peer community.
4. Reflect the need back separately from the method: the need is legitimate even if the method is unproven.
5. Ask about past experience of mental health care, especially any negative experience that makes a "natural" option feel safer.
Example language (illustrative): "What are you hoping the capsules will do for you?" / "It sounds like what matters most is not going back to how you felt after your first baby, and doing that in a way that feels natural and in your control. Have I got that right?"
Watch for: high personal stakes on the outcome ("if it doesn't work, it's me"), distrust of medical care that might delay help, pressure from a provider or group. Working when: the client can name the need apart from the product and is curious about other ways to meet it.

4.3 Supporting an informed, values-based decision without coercion

Purpose / when: when the client is still deciding, or asks "what do you think?". The psychotherapist offers balanced information and decision process, not a recommendation either way. No placenta-specific decision aid is cited here; use general shared-decision principles. [source: NICE CG192 1.4.3, 1.4.6, 1.4.7; synthesis]
Steps:
1. Ask permission to share what research and public-health bodies say.
2. Summarise in plain terms, attributing each point: no good evidence of benefit for mood, energy, milk or iron (Northwestern 2015; UNLV 2017); in the largest study consumers had slightly higher depression screening scores, probably because more worried or at-risk women choose it (Benyshek et al. 2023); CDC reported a baby who developed a second, late-onset GBS blood infection linked to the mother's capsules and advises avoiding them; processing is unregulated in the US. Use absolute figures where available (e.g. 9.9% vs 8.4% screening above threshold), as NICE recommends.
3. Separate the questions: (a) is this safe and wise for me and the baby; (b) what else will protect my mood; (c) how will I honour the placenta's meaning.
4. Encourage the client to discuss infection risks with the midwife or obstetrician and baby's doctor, who can speak to their own test results.
5. Record that information was given and that the decision is the client's.
Example language (illustrative): "I'm not the person to tell you what to do with your placenta, and I don't sell or recommend any of these services. Would it help if I shared what the research and the CDC have said, and then we think through what fits your values?" / "Whatever you decide, can we make sure your mood plan doesn't rest on the capsules alone?"
Watch for: the therapist drifting into persuasion or ridicule (rupture risk); the client feeling the therapist has "taken sides" with doctors; decisions made under group or provider pressure. Working when: the client can state the main uncertainty in their own words and has spoken to the maternity team.

4.4 Building a perinatal mental health plan that does not depend on capsules

Purpose / when: any client hoping capsules will prevent "baby blues" or depression; anyone with past depression, anxiety or severe mental illness. [source: NICE CG192 1.5.4–1.5.12; Benyshek et al. 2023]
Steps:
1. Ask about past or present severe mental illness and family history (NICE 1.5.9); refer to a specialist perinatal service if suspected or past severe illness (1.5.10).
2. Use the two NICE depression questions (low mood, loss of interest) and the GAD-2 at booking and early postnatal contact; if positive, use the EPDS or PHQ-9 as part of a full assessment, or refer to the GP (1.5.4–1.5.5). Use licensed instruments as issued; do not improvise items.
3. Agree monitoring points in the postnatal weeks (1.5.8).
4. Agree what the client will do if mood drops, regardless of capsule use: who to call, which symptoms mean same-day help.
5. Add the factors the 2023 study authors flag: social support, stress, sleep and breastfeeding difficulties.
6. If treatment is needed, follow NICE: facilitated self-help for mild to moderate depression, high-intensity CBT and/or medication (discussed with the prescriber) for moderate to severe, trauma-focused CBT or EMDR for PTSD after traumatic birth (1.8.1, 1.8.3, 1.9.5).
Example language (illustrative): "Let's treat the capsules as your own choice and build a safety net that works whether or not they do anything." / "If you notice two weeks of low mood or losing interest, that's our signal to act, not a sign the capsules failed you."
Watch for: postponing help ("I'll give the capsules a chance first"); attributing improvement or deterioration to capsules; red flag: sudden onset of confusion, unusual beliefs, hallucinations or marked agitation in the first weeks after birth, especially with a history of bipolar disorder or psychosis, needs referral for assessment within 4 hours (NICE 1.5.11–1.5.12). Working when: screening happens on schedule and any treatment need leads to action.

4.5 Coordinating with the maternity team, baby's doctor and pharmacist (with consent)

Purpose / when: whenever a placenta plan exists, and urgently if the baby or parent becomes unwell. CDC asks clinicians to inquire about placenta ingestion in late-onset GBS infection and to counsel mothers who are GBS-colonised, had chorioamnionitis or whose baby had early-onset GBS. [source: CDC MMWR 2017]
Steps:
1. Seek consent to share the plan with the midwife or obstetrician (and later the paediatrician or health visitor).
2. Share facts only: the plan, the client's questions, and that the client would like infection-risk advice in light of their own results. Do not advise on taking, stopping or changing any product or medicine; route those questions to the prescriber, midwife or pharmacist.
3. If the client takes prescribed medicines (e.g. antidepressants) and asks about combining them with capsules, route to the prescriber or pharmacist. [synthesis]
4. Record consent, what was shared and with whom.
Example language (illustrative): "Would you be OK with me letting your midwife know about your placenta plan? They have your test results and can talk through infection risks in a way I can't." / "That's a really good question for your pharmacist; shall we write it down so you don't forget?"
Watch for: the client concealing the plan from the maternity team because of expected disapproval (explore, don't override); the therapist being asked to "approve" a product. Working when: the client reports a medical conversation took place.

4.6 Recognising and responding to risk

Purpose / when: throughout the perinatal period. [source: CDC MMWR 2017; NICE CG192; synthesis]
Steps:
1. Unwell baby: if the client describes a baby who is irritable, feeding poorly, feverish or "not right", especially after an earlier infection, direct them to urgent medical care that day and encourage them to mention capsule use (the CDC case presented with irritability). Do not reassure or assess medically.
2. Severe mental illness: see 4.4 (postpartum psychosis needs referral for assessment within 4 hours).
3. Substitution of care: if a client is declining assessment or treatment for depression because they are relying on capsules, name the concern, revisit 4.3 and 4.4, and involve the GP with consent.
4. Financial and group pressure: notice expensive packages, upselling, or a peer community that frames refusal as weakness or medical care as failure.
5. Safeguarding: if a baby is unwell and medical care is being withheld, follow local child-safeguarding procedures. Placenta use by itself is not a safeguarding matter. [synthesis]
Example language (illustrative): "What you're describing in the baby needs a doctor today, not tomorrow. Please mention the capsules too; it's one of the things they'll want to know."
Watch for: your own anxiety turning into medical advice; minimising a parent's concern about the baby. Working when: the family seeks timely care and the medical team has the history.

4.7 Health anxiety, contamination fears and somatic preoccupation (cross-ref Domain II)

Purpose / when: when information about infection risk triggers intrusive fears or checking about the baby, or when postpartum bodily sensations (fatigue, bleeding, "hormone crash") are read as depletion requiring correction. [synthesis; see Domain II for health anxiety and somatic symptom protocols]
Steps:
1. Distinguish proportionate concern (one conversation with the midwife) from repeated reassurance-seeking, checking or avoidance.
2. If perinatal OCD or health anxiety is suspected, assess and use the established CBT approaches in Domain II (formulation, reducing reassurance-seeking, behavioural experiments), under NICE CG192 pathways for anxiety disorders (1.8.8–1.8.9).
3. Normalise ordinary postpartum fatigue while ensuring medical causes are checked by the GP or midwife.
Example language (illustrative): "It makes sense that the CDC report frightened you. Let's look at what you've been doing to feel safe, and whether it's helping or keeping the fear going."
Watch for: the therapist inadvertently supplying reassurance loops. Working when: checking and reassurance-seeking reduce and the client can tolerate uncertainty.

4.8 Meaning, ritual, grief and regret

Purpose / when: when the placenta has spiritual, cultural or family meaning; when the client could not keep it (birth-setting policy, medical reasons, change of mind); or after harm (infant infection) or disappointment ("it didn't help"). [source: NHS Wales guideline 1005 for personal, spiritual and cultural reasons; synthesis]
Steps:
1. Invite the story of what the placenta means to them and their family.
2. For loss or disappointment, allow grief without arguing about efficacy.
3. After an infant infection: address guilt and self-blame ("I made my baby ill"), NICU or hospital trauma, and couple or family blame; screen for PTSD and depression (NICE 1.9.5, 1.5.4).
4. If the client wants a way to honour the placenta, explore their own cultural or spiritual practices; the therapist does not prescribe rituals. NHS Wales notes remains are human tissue and that burial has legal and health-and-safety guidance from the health board.
Example language (illustrative): "You made that choice to look after yourself and your baby, with the information you had. Can we make room for how painful it is that it turned out this way?"
Watch for: rumination, intrusive images of the baby's illness, avoidance of the baby, relationship conflict. Working when: self-blame softens and the client can hold both care for themselves and grief.

4.9 Managing commerce and conflicts of interest

Purpose / when: when a client's doula, friend or online group sells encapsulation or training, or when the therapist is also a birth worker. Training routes are fee-based with annual membership and marketed as "the most comprehensive" or "highest safety standards" (organisations' own claims). [source: ProDoula training page; APPA profile]
Steps:
1. The psychotherapist holds no financial interest and does not refer to named providers.
2. If a therapist also offers birth services, keep roles separate and do not offer placenta services to psychotherapy clients. [synthesis; profession's ethics code on multiple relationships and conflicts of interest not verified here]
3. Help clients notice sales pressure (upsells, urgency, testimonials) and their right to decline or cancel.
Example language (illustrative): "It can be hard to say no to someone who has supported you through the pregnancy. What would you want if nobody's feelings were at stake?"
Watch for: clients who fear losing their doula's support if they decline. Working when: the decision feels like the client's own.

4.10 Reporting routes

Purpose / when: when a product appears to have caused illness, when health claims are made in advertising, or when a provider is unregistered. [synthesis unless cited]
Steps:
1. Illness linked to a product: encourage the family to tell the treating doctor, who can notify public health. In the CDC case the state health authority (Oregon Health Authority) was notified and investigated. [source: CDC MMWR 2017]
2. UK: food-business registration and hygiene sit with local authority environmental health and the FSA (NHS Wales; British Journal of Midwifery 2014). Advertising claims: Advertising Standards Authority [uncertain: not verified].
3. US: state or local health department for illness; FTC for deceptive health advertising [uncertain: not verified].
4. A professional's conduct (e.g. a regulated nurse, midwife or therapist promoting it as treatment): the relevant professional regulator [synthesis].
5. Child protection concerns: local safeguarding procedures.
Example language (illustrative): "Would you like help thinking through who to tell about what happened, so it's on record?"
Watch for: pressing a reluctant client to report; reporting is usually the client's decision unless a safeguarding duty applies. Working when: the client feels informed and supported either way.

5. Handling problems

Sources do not address psychotherapy problems with this practice directly; all responses below are [synthesis] unless a source is named.

Client feels judged and goes quiet after you share the research. Repair: name it ("I think I came across as against your plan; that's not my job here"), return to their hopes (4.2), and re-state that the decision is theirs. Prevention: ask permission before sharing information.
Client insists capsules will prevent depression and declines screening. Do not argue efficacy repeatedly. Agree a minimal plan: "take them if you choose, and also let me ask the two mood questions every few weeks". If depression develops, act on NICE pathways regardless. [source: NICE CG192 1.5.4, 1.5.8]
Client credits capsules for improvement. Do not dispute; widen attribution (sleep, support, time, their own coping) so gains are not lost if capsules stop. The UNLV trial authors noted small mood and fatigue differences not distinguishable from placebo. [source: UNLV 2017]
Client blames themselves when mood worsens despite capsules. Normalise that postpartum depression is common and not caused by "wrong" choices; treat the depression; note the 2023 study suggests higher-risk women are more likely to choose capsules, not that the choice caused depression. [source: Benyshek et al. 2023]
Client conceals the plan from midwife or baby's doctor. Explore the fear (judgement, conflict); rehearse a short disclosure; respect the choice unless a baby is unwell, in which case urge disclosure to the treating doctor (4.6).
Overwhelm from conflicting advice (provider, peers, internet, clinicians). Slow down; separate the three questions in 4.3; limit research time; identify one trusted medical contact.
Partner or family conflict (one wants it, the other finds it distasteful or unsafe). Use a couple session to surface values and fears; keep focus on shared goals for the parent's recovery and baby's safety.
Group or provider pressure, sunk cost ("I've already paid"). Explore the cost of continuing vs stopping; the therapist does not advise on stopping any product but supports the client to ask the medical team.
Rupture with a client who is also a birth worker or encapsulator. Be transparent that you neither endorse nor condemn their work; focus on their therapy goals; manage dual-relationship risk.
Therapist's own reactions (disgust, alarm, or enthusiasm). Notice and contain them; use supervision. Disgust in particular can leak through as ridicule and damage the alliance.
Infant became ill. See Harm account below; prioritise medical care, then grief, guilt, trauma and family conflict (4.8).

Harm account

What was actually done

Oregon, 2016 (CDC MMWR, published 30 June 2017). A term baby was born after an uncomplicated pregnancy; the mother's late-pregnancy GBS screen was negative. Before delivery she had registered with an encapsulation company ("Company A") to collect and process her placenta. Shortly after birth the baby had breathing difficulty, went to the NICU and was found to have GBS in the blood; the baby completed a course of intravenous antibiotics and went home. Three days after birth the mother had received her capsules and began taking them. Five days after the baby's antibiotics ended, the baby was brought to an emergency department because of irritability and was admitted to a second hospital with GBS in the blood again. No other source was found (spinal fluid and breast milk were negative). The company's website described its own processing and storage of the capsules; it screened for some prior infections but did not ask about infections during or after labour. The mother's doctor told her to stop taking the capsules. The Oregon Health Authority was notified in September 2016. [source: CDC MMWR 2017]
United Kingdom, 2014. Local council officers, citing a Staphylococcus aureus risk, served two Hygiene Emergency Prohibition Notices on the director of the Independent Placenta Encapsulation Network (IPEN), which sold capsules and placenta smoothies; in May 2014 a district judge confirmed an order that raw placenta must not be processed for human consumption. The FSA then said it considered placenta a novel food. IPEN argued placenta helps milk production, bleeding and postnatal depression. [source: British Journal of Midwifery 2014]

How it caused harm

Mechanism (CDC): the processing did not eliminate the bacteria. GBS was grown from the capsules, and the capsule isolate was genetically indistinguishable from both of the baby's blood isolates (identical by pulsed-field gel electrophoresis and with no single-nucleotide differences on whole-genome sequencing). The strain (serotype III, ST17) carried virulence factors that may aid gut invasion and possibly crossing into the brain. CDC concluded the late-onset infection was due to high maternal colonisation from eating contaminated placental tissue, while noting that transmission from other colonised household members could not be ruled out, and that heat treatment commonly used against Salmonella in meat may not have been enough to reduce GBS. [source: CDC MMWR 2017]
Documented injury: a second hospital admission for bloodstream infection in a newborn, requiring a further course of two intravenous antibiotics. The baby was discharged home. [source: CDC MMWR 2017]
Who is most at risk: babies of mothers who are GBS-colonised, who had chorioamnionitis, or whose babies already had early-onset GBS (CDC); breastfeeding infants generally, for whom risks are unstudied (Northwestern 2015). [source: CDC MMWR 2017; Northwestern 2015]
Unknown and indirect harms: no studies had examined risks; dosing varies and women "don't really know" what they ingest (Northwestern review authors). Capsules modestly raised some hormone levels, of unknown significance (UNLV 2017). Psychological risk: reliance on capsules may displace or delay screening and treatment for postpartum depression; consumers had slightly higher depression screening scores in a large cohort (likely selection, causality not excluded). [source: Northwestern 2015; UNLV 2017; Benyshek et al. 2023]
Psychological sequelae for families: not documented in the sources; clinically, expect guilt, self-blame, medical trauma after NICU care and couple conflict [synthesis].

Recognising it today

Marketing language: capsules as "like a daily vitamin"; "rebalance hormones"; "prevent baby blues"; "boost milk supply"; "replenish iron"; "TCM" or "Traditional" warming methods; "honouring the placenta"; "fourth trimester" self-care; appeals to other mammals. [source: Bornbir provider guide; ProDoula training page; UNLV 2017]
Safety signals that are not safety standards: bloodborne-pathogens and food-handler certificates and claims of "the highest safety standards in the industry" describe the provider's training, not a validated process; CDC states no processing standards exist in the US. [source: ProDoula training page; APPA profile; CDC MMWR 2017]
Intake gaps: a provider who does not ask about infection during labour, chorioamnionitis, or the baby's early illness (as in the CDC case). [source: CDC MMWR 2017]
Red flags in a colleague's or group's practice: recommending placenta capsules for postpartum depression or anxiety; selling or receiving referral fees; discouraging screening, medication discussions or medical review; framing a baby's illness as unrelated without medical input. [synthesis]
How legitimate care differs: there is no evidence-based therapeutic version of placenta ingestion. Legitimate care offers screening and NICE-recommended treatment for perinatal mental health, and leaves infection-risk decisions to the maternity and paediatric team. Non-ingestive honouring of the placenta (e.g. burial in line with health-board guidance) carries none of the ingestion risks described here. [source: NICE CG192; NHS Wales guideline 1005; synthesis]

What to do instead and how to help those harmed

For mood, energy and recovery: NICE CG192 pathways: two-question depression check and GAD-2, EPDS or PHQ-9 within full assessment; facilitated self-help, CBT, IPT, medication discussed with the prescriber; trauma-focused CBT or EMDR after traumatic birth; specialist perinatal services and mother-and-baby units for severe illness. Address the 2023 study's flagged factors: social support, stress, sleep and breastfeeding difficulties. [source: NICE CG192; Benyshek et al. 2023]
For infection risk: route questions to the midwife, obstetrician and paediatrician; CDC advises that capsule ingestion should be avoided and that clinicians ask about it in late-onset GBS. [source: CDC MMWR 2017]
Helping affected families: ensure medical follow-up is in place; assess the parent for depression, anxiety and PTSD (NICE 1.5.4, 1.9.5); work with guilt and self-blame using compassion-focused or CBT methods; support the couple where blame arises; acknowledge NICU-related trauma; consider the other parent's mental health. [source: NICE CG192; synthesis]
Ethical, reporting and legal duties: do not sell, recommend or perform the service; document information given and consent for any disclosure; support reporting of illness to public health through the treating doctor (Oregon Health Authority investigated in the CDC case); in the UK, local authority environmental health and the FSA oversee food-business hygiene; follow safeguarding procedures where a baby's medical care is withheld. Advertising and consumer regulators (ASA, FTC) [uncertain: not verified]. [source: CDC MMWR 2017; NHS Wales guideline 1005; British Journal of Midwifery 2014; synthesis]

Sources

← Previous · XII-147Unapproved stem-cell and exosome clinics Next · XII-149 →Off-label hyperbaric oxygen